Clinical diagnostic focus CombiMatrix operates as a cytogenetic and cytogenomic laboratory specializing in prenatal diagnosis, miscarriage analysis, pediatric developmental disorders and preimplantation genetic testing, presenting opportunities to cross-sell advanced genetic testing services and expand offerings to fertility clinics and OB-GYN practices.

Expansion opportunities Historical acquisitions and product launches indicate growth activity and potential integration with prenatal and PGD/PGS workflows; target collaboration with fertility centers, IVF clinics, and hospital systems seeking end-to-end cytogenomic solutions.

Strategic partnerships As a clinical laboratory with expertise in SNP microarray and custom testing, there is potential to partner with larger biotechs or hospitals for co-development or referral networks, leveraging Invitae-style scale while offering specialized cytogenomic capabilities.

Financial health signals Revenue range of ten to twenty-five million with a moderate company size suggests room for upsell of higher-margin services, expanded test menus, and value-based offerings to drive higher per-test margins for clinics and ambulatory centers.

Tech and analytics readiness Current tech stack includes AWS, analytics and tracking tools; this indicates capability to leverage data-driven service improvements and digital marketing to attract new clinic clients, plus potential to offer standardized data reporting and decision-support tools.